Element 8.13
Wearables and continuous monitoring
- Sheet
- 8.13
- Chapter
- 8 Health and care
- State
- Drafted
- Release
- 16 November 2026
- Editor
- Contributed by Praecise as open research
- Reviewers
- To be named at review
- Safety
- S3, as the chapter
- Licence
- CC BY-SA 4.0
- Resources
- 4
The element
- Requirement
Where members use wearable or continuous monitors, the devices are authorised for the use made of them, decisions based on their readings are made with a clinician, and the data they produce stays under the person's control. This page describes how a community organises; it gives no medical advice.
- How to tell
Each device's intended use is known from its authorisation. In March 2024 the FDA cleared the first continuous glucose monitor sold over the counter, for adults who do not use insulin, including people without diabetes; it is not for people with problematic low blood sugar, it does not alert for low glucose, each sensor is worn up to 15 days, and the FDA states that users should not make medical decisions on its output without their health care provider (FDA Clears First Over-the-Counter Continuous Glucose Monitor). In 2023 WHO, for the first time, advised including personal-use glucose monitoring devices in its essential diagnostics list (WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters).
- Options
Monitors prescribed by a clinician. Used within a care plan.
Over-the-counter monitors. Within the limits of their authorisation (FDA Clears First Over-the-Counter Continuous Glucose Monitor).
Self-care with support. WHO's self-care guideline places self-monitoring inside a supported system (WHO guideline on self-care interventions for health and well-being, 2022 revision).
Data held by the person. In the European Union the European Health Data Space gives people free access to their electronic health data and the right to share it, with an opt-out from secondary use (European Health Data Space Regulation (EHDS)).
- Settled, open, contested
Settled. Continuous glucose monitors are authorised medical devices with stated intended uses (FDA Clears First Over-the-Counter Continuous Glucose Monitor).
Open. The benefit of continuous monitoring for people without diabetes. The FDA clearance permits the use; no source opened in this work shows health outcomes for it.
Contested. Whether wide use of consumer monitors improves health or adds worry and cost. No source opened here settles it.
The four stages
Learn: the device's intended use and limits (FDA Clears First Over-the-Counter Continuous Glucose Monitor) and the place of self-testing (WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters, WHO guideline on self-care interventions for health and well-being, 2022 revision). Design: a rule that readings are discussed with a clinician; a data rule (8.8). Build: charging and connectivity (domains 5, 14). Deploy: review with the provider.
Resources at each stage
1 Learn
Understand
- European Health Data Space Regulation (EHDS) Framework, S1
- FDA Clears First Over-the-Counter Continuous Glucose Monitor Case study, S3
- WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters Guide, S3
- WHO guideline on self-care interventions for health and well-being, 2022 revision Guide, S2
What changes between 30 adults and 300 people
Monitoring is personal at both scales. With 300 people, the community may host a telemedicine link so readings can be reviewed with a clinician (8.3), and needs a clear rule that no one else sees another person's data.
Reference designs
Open for contributions Designs with drawings, specifications and a bill of materials. Add to it
Parts list
Every resource that supports this element. Those marked External carry the label “External resource. Not made or verified by Public Protocol”.
| Resource | Type | Origin | Maturity | Safety | Licence, as stated at its source |
|---|---|---|---|---|---|
| European Health Data Space Regulation (EHDS) | Framework | External | Established | S1 | Not stated on the page opened |
| FDA Clears First Over-the-Counter Continuous Glucose Monitor | Case study | External | Working | S3 | Not stated on the page opened |
| WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters | Guide | External | Established | S3 | Not stated on the page opened |
| WHO guideline on self-care interventions for health and well-being, 2022 revision | Guide | External | Established | S2 | CC BY-NC-SA 3.0 IGO |
Depends on, and completes
It is one of 22 elements that complete Health and care.
The standing questions
Who pays for sensors. Who reads the data. Who owns it: the person.
Environments
Islands and coasts, Arctic cold, hot deserts, tropical humid forest, temperate forest, high altitude, flood plains and other harsh settings: no source found in this work. Operating temperature limits are in each maker's instructions.
Safety
State and evidence
Drafted
An editor has written the element's text from the resources listed under it, citing them. It is checked when it is reviewed.
Evidence from a real place or system is recorded here, with what did not work. What the states mean
History
- Drafted in the release of 16 November 2026.